<DOC>
	<DOCNO>NCT02085967</DOCNO>
	<brief_summary>This study single center , open-label , drug-drug interaction study healthy male female subject . The study consist 2 part . In Part A , effect steady-state dose strong CYP3A inhibitor ( itraconazole ) inducer ( rifampin ) pharmacokinetics E2006 metabolite assess . Approximately 30 subject sequentially assign 1 2 treatment group receive itraconazole rifampin equal number ( approximately 15 subject per group ) . The itraconazole treatment group fully enrol enrollment initiate rifampin treatment group . In Part B , effect steady-state dose E2006 pharmacokinetics midazolam , substrate CYP3A , plus bupropion , substrate CYP2B6 , assess approximately 24 subject . The 2 study part conduct parallel .</brief_summary>
	<brief_title>A 2-Part Study Assess Potential Metabolism-Based Drug-Drug Interactions E2006 When Coadministered With Itraconazole , Rifampin , Midazolam , Bupropion</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet follow criterion include study : 1 . Healthy male female , age 18 55 year 2 . Body mass index great 18 less equal 32 kg/m2 Screening 3 . All female must nonchildbearing potential 4 . Males abstinent undergone successful vasectomy , partner woman childbearing potential must use , partner must use , highly effective method contraception 5 . Are willing able comply aspect protocol 6 . Provide write informed consent Exclusion Criteria Subjects meet follow criterion exclude study : 1 . Any subject know history malaria travel country know malarial risk ( ie , designate `` high '' `` moderate '' risk country accord list available http : //www.cdc.gov/malaria ) within last year 2 . Subjects history bowel resection , malabsorptive disorder , severe gastroparesis , gastrointestinal procedure purpose weight loss ( include LAPBANDTM ) , would slow gastric empty potentially affect PK profile E2006 3 . Subjects know history clinically significant drug food allergy 4 . Subjects experience weight loss gain great 10 % Screening prior dose 5 . Subjects clinically significant illness require medical treatment within 8 week clinically significant infection within 4 week dose 6 . Subjects clinically abnormal symptom organ impairment find medical history , symptom sign , vital sign measurement , electrocardiogram ( ECG ) finding , laboratory test result require medical treatment find medical history screen baseline 7 . Subjects know positive human immunodeficiency virus , subject positive hepatitis B hepatitis C screen test result 8 . Subjects history drug alcohol dependency abuse ( define The Diagnostic Statistical Manual Mental Disorders V criterion ) within approximately 2 year prior Screening , positive urine drug test result Screening Baseline 9 . Subjects receive blood product within 4 week , donate blood within 8 week , donate plasma within 1 week dose 10 . Subjects use hormonal replacement therapy within 3 month prior dose 11 . Subjects use drug , overthecounter ( OTC ) medication , nutritional supplement ( eg , product contain St John 's wort ) , excessive dos vitamin ( opinion principal investigator ) , herbal preparation , food beverage know modulate CYP ( eg , CYP3A4 ) transporter within 4 week prior dose , unwilling abstain use study 12 . Subjects engage intense physical activity within 1 week prior Baseline ( eg , weight training ) 13 . Subjects smoke used tobacco nicotinecontaining product within 3 month prior dose 14 . Subjects habitually consume 400mg caffeine per day 15 . Subjects participate ( receive investigational product ) another clinical trial le 1 month ( 5 elimination halflives investigational product ) prior dose currently enrol another clinical trial 16 . Subjects disease may influence outcome study , psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , subject congenital abnormality metabolism , subject condition would make , opinion investigator , unsuitable study , opinion investigator , likely complete study reason Restrictions concomitant medication , food beverage : 17 . Prescription drug prohibit within 4 week dose OTC medication within 2 week prior dose Termination Visit 18 . Smoking use tobacco nicotinecontaining product prohibit within 4 week prior dose Termination Visit 19 . Intake caffeinated beverage food prohibit 72 hour prior dose throughout entire study 20 . Intake nutritional supplement , juice , herbal preparation food beverage may affect various drug metabolize enzyme transporter ( eg , alcohol , grapefruit , grapefruit juice , grapefruitcontaining beverage , apple orange juice , vegetables mustard green family [ eg , kale , broccoli , watercress , collard green , kohlrabi , Brussels sprout , mustard ] charbroiled meat ) prohibit within 2 week prior dose Termination Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Drug-Drug Interactions</keyword>
</DOC>